Sangamo Therapeutics, Inc. (SGMO)
0.149
0.00 (0.00%)
USD |
OTCM |
Jun 10, 16:00
Sangamo Therapeutics Enterprise Value : 53.47M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 53.47M |
| June 09, 2026 | 53.95M |
| June 08, 2026 | 63.00M |
| June 05, 2026 | 80.81M |
| June 04, 2026 | 79.01M |
| June 03, 2026 | 81.31M |
| June 02, 2026 | 80.40M |
| June 01, 2026 | 79.26M |
| May 29, 2026 | 81.93M |
| May 28, 2026 | 78.08M |
| May 27, 2026 | 74.60M |
| May 26, 2026 | 68.43M |
| May 22, 2026 | 63.96M |
| May 21, 2026 | 56.38M |
| May 20, 2026 | 56.38M |
| May 19, 2026 | 52.60M |
| May 18, 2026 | 44.61M |
| May 15, 2026 | 47.68M |
| May 14, 2026 | 47.88M |
| May 13, 2026 | 50.74M |
| May 12, 2026 | 48.26M |
| May 11, 2026 | 41.87M |
| May 08, 2026 | 39.39M |
| May 07, 2026 | 33.63M |
| May 06, 2026 | 47.34M |
| Date | Value |
|---|---|
| May 05, 2026 | 37.90M |
| May 04, 2026 | 65.32M |
| May 01, 2026 | 47.67M |
| April 30, 2026 | 41.13M |
| April 29, 2026 | 46.76M |
| April 28, 2026 | 75.02M |
| April 27, 2026 | 78.74M |
| April 24, 2026 | 70.50M |
| April 23, 2026 | 97.39M |
| April 22, 2026 | 98.59M |
| April 21, 2026 | 98.42M |
| April 20, 2026 | 103.64M |
| April 17, 2026 | 100.29M |
| April 16, 2026 | 103.60M |
| April 15, 2026 | 105.71M |
| April 14, 2026 | 97.72M |
| April 13, 2026 | 98.21M |
| April 10, 2026 | 95.81M |
| April 09, 2026 | 100.24M |
| April 08, 2026 | 97.26M |
| April 07, 2026 | 97.84M |
| April 06, 2026 | 107.16M |
| April 02, 2026 | 116.07M |
| April 01, 2026 | 99.50M |
| March 31, 2026 | 94.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| INmune Bio, Inc. | 12.32M |
| Bolt Biotherapeutics, Inc. | 7.729M |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sarepta Therapeutics, Inc. | 1.979B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.00M |
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 32.44M |
| EPS Diluted (Quarterly) | -0.0796 |
| Gross Profit Margin (Quarterly) | 39.18% |
| Profit Margin (Quarterly) | -2.15K% |
| Earnings Yield | -257.0% |
| Normalized Earnings Yield | -239.46 |